Capricorn Partners, headquartered in Leuven, has announced the first close of its Capricorn Health-tech Fund II, raising €51 million to support innovative health technology startups.
Capricorn Health-tech Fund II builds upon the success of its predecessor, aiming to invest in groundbreaking companies specialising in health technology, medical devices, digital health, and diagnostics.
“With Capricorn Healthtech Fund II, we invest in healthcare transformers and facilitate their integration into mainstream healthcare practices, making healthcare more accessible and efficient,” comments Filip Pintelon, Investment Partner Health with the Capricorn Healthtech team.
Founded in 1993, Capricorn Partners is an investment firm noted for its focus on venture capital, particularly in the fields of technology, life sciences, and clean-tech innovation. This has led to notable exits like Cartagenia, Bluebee and Sequana Medical and success stories like icometrix.
The newly raised funds will be channelled into early and growth-stage companies in the health-tech sector. Capricorn Partners emphasised the importance of scaling companies that can make a significant impact in healthcare, including advancing patient outcomes and optimising medical processes.
This approach aligns with the growing demand for cost-effective, innovative healthcare solutions in Europe and beyond.
According to Capricorn, the personalisation of health care is a key factor in reducing cost and improving service for patients. The European Commission’s 2024 report on healthcare highlights that expenditure on health accounts for approximately 10% of the GDP in most EU countries.
Technologies such as AI allow for the personalisation of healthcare across the entire patient journey, from prevention and diagnosis to treatment. They enable healthcare providers to deliver tailored services more efficiently, improving the quality of care and patient satisfaction.
By adopting these innovative technologies, Capricorn argues that healthcare systems could achieve significant cost savings while maintaining a high standard of personalised care.
Among the new LPs joining the fund are Invest-NL and Sensinnovat, “Invest-NL is committed to driving the essential transition in healthcare by investing in innovations that prevent, replace or shift expensive care. Capricorn Partners brings the expertise needed to guide this process effectively, making them a valuable partner within our ecosystem.” says Ulrike Kostense, Lead Indirect Investments.
Also Geert Reynders, Chief Investment Officer at Sensinnovat comments: “We are excited to partner with Capricorn Healthtech Fund II, as it aligns with our commitment to investing in healthtech solutions that improve lives and strengthen healthcare systems worldwide”.
They join existing cornerstone investors Quest for Growth, AG Insurance/Ageas, PMV, finance&invest.brussels and the KU Leuven Research & Development.
“Our investment in the Capricorn Healthtech Fund II aligns perfectly with the strategy of Ageas and AG Insurance to invest in the real economy and to follow the latest developments in health and technology, and furthermore illustrates the longstanding partnership with Capricorn Partners” according to Gilke Eeckhoudt, Chief Development & Sustainability Officer Ageas and Wim Vermeir, Chief Investment Officer AG Insurance.
This first closing of Capricorn Healthtech Fund II is just the beginning for Capricorn – their goal is to establish a €100+ million fund.
Read the orginal article: https://www.eu-startups.com/2025/01/capricorn-partners-secures-e51-million-for-health-tech-fund-iis-first-close/
